New treatments outperforming placebo becoming less common

June 14, 2013
New treatments outperforming placebo becoming less common
The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

Explore further: Pace of new drug advances may be slowing, study finds

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pace of new drug advances may be slowing, study finds

June 4, 2013
(HealthDay)—The drugs emerging from clinical trials in recent years seem less impressive than those developed in decades gone by, a new review finds.

Placebo often effective for treating headache in children

January 29, 2013
(HealthDay)—Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies published online ...

Topical anesthetics effective for premature ejaculation

April 12, 2013
(HealthDay)—Topical anesthetic agents seem to be effective and are generally well tolerated for patients with premature ejaculation (PE), according to a review published in the April issue of Urology.

Collagenase clostridium histolyticum OK in Peyronie's

April 26, 2013
(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal ...

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients

May 27, 2011
The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking ...

Recommended for you

Sugar not so sweet for mental health

July 27, 2017
Sugar may be bad not only for your teeth and your waistline, but also your mental health, claimed a study Thursday that was met with scepticism by other experts.

Could insufficient sleep be adding centimeters to your waistline?

July 27, 2017
Adults in the UK who have poor sleep patterns are more likely to be overweight and obese and have poorer metabolic health, according to a new study.

Vitamin E-deficient embryos are cognitively impaired even after diet improves

July 27, 2017
Zebrafish deficient in vitamin E produce offspring beset by behavioral impairment and metabolic problems, new research at Oregon State University shows.

The role of dosage in assessing risk of hormone therapy for menopause

July 27, 2017
When it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered—taking a pill versus wearing a patch on one's skin—doesn't affect risk or benefit, researchers at UCLA and elsewhere ...

Blowing smoke? E-cigarettes might help smokers quit

July 26, 2017
People who used e-cigarettes were more likely to kick the habit than those who didn't, a new study found.

Brain disease seen in most football players in large report

July 25, 2017
Research on 202 former football players found evidence of a brain disease linked to repeated head blows in nearly all of them, from athletes in the National Football League, college and even high school.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JRi
5 / 5 (1) Jun 15, 2013
Probably something to do with more strict guidelines, how tests need to be carried out nowadays. Laws require to inform authorities in advance when starting new tests. More difficult for pharmaceutical companies to "forget" the trials that failed to give positive outcome.
Wolf358
5 / 5 (1) Jun 15, 2013
Maybe it's all of the new improved extra-strength placebos....

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.